Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
7.
Skin Pharmacol Physiol ; 31(4): 184-187, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29649806

RESUMO

BACKGROUND: Chronic spontaneous urticaria (CSU) is a frequent mast cell-driven disease that affects approximately 0.5-1% of the population. Antihistamines are currently the drugs of choice in patients with CSU. Omalizumab has been shown to be very effective in CSU and has been recently approved as second-line therapy. However, although its introduction has markedly improved the therapeutic possibilities for CSU, there is still a hard core of patients who do not respond and require effective treatment. METHODS: We report the case of a patient who achieved an 8-month remission of refractory CSU following the use of rituximab, and perform a review of the literature regarding the use of rituximab in CSU. RESULTS: There was a remarkable improvement in her CSU after the administration of rituximab maintained over time. CONCLUSION: Rituximab is a chimeric murine/human monoclonal antibody directed against CD20, which depletes memory B-lymphocytes that are necessary for autoantibody production. The abrogation of the autoantibody production is the proposed mechanism by which it may alleviate the symptoms of CSU.


Assuntos
Fatores Imunológicos/uso terapêutico , Rituximab/uso terapêutico , Urticária/tratamento farmacológico , Adulto , Autoanticorpos/imunologia , Doença Crônica , Feminino , Humanos , Fatores Imunológicos/farmacologia , Rituximab/farmacologia , Resultado do Tratamento , Urticária/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...